The IBT Nomination Committee presented its proposals to the AGM in April 2018, which will be held on May 15, 2018.
The Nomination Committee has subsequently been informed that Nasdaq Stockholm, within the framework of IBT’s listing application to the Nasdaq Main Market, has recommended that IBT’s Board must consist of a larger proportion of members who are not directly or indirectly dependent on BioGaia AB. The Nomination Committee has therefore resumed its work with the aim of further strengthening the Board of Directors and meeting the stock exchange’s recommendation.
In view of the above, the Nomination Committee has decided to modify its proposal by proposing that Lilian Henningson Wikström and Kristina Sjöblom Nygren be elected as new Board members in IBT. The Nomination Committee proposes unchanged re-election of Peter Rothschild, Anders Ekblom, Margareta Hagman, Eva Idén and Anton Jahreskog. Jan Annwall has declined re-election to the Board. The proposal therefore means that the Board of Directors shall have seven elected members without deputies.
Lilian Henningson Wikström, born 1961, holds a Master of Science from Åbo Akademi University and is a Doctor of Medical Sciences from Karolinska Institutet. Since 2010 she has been CEO of Karolinska Institutet Innovations AB in Solna. Lilian Henningson Wikström has, in addition to being a PhD at the Ludwig Institute for Cancer Research in Stockholm, been active in the pharmaceutical industry, among other positions has been research director at NeuroNova AB. Lilian Henningson Wikström does not own any shares in IBT. Lilian Henningson Wikström is judged to be independent both in relation to major shareholders and to the company and company management.
Kristina Sjöblom Nygren, born 1961, has received a Doctor of Medical Sciences from Karolinska Institutet and is a licensed physician. She has been Chief Medical Officer, Head of Development, since 2018 at Santhera Pharmaceuticals in Basel, Switzerland. Kristina Sjöblom Nygren has extensive experience from the pharmaceutical industry, where she has held among other positions Head of Clinical Development at SOBI. Kristina Sjöblom Nygren does not own any shares in IBT. Kristina Sjöblom Nygren is considered to be independent both in relation to major shareholders and to the company and company management.
The Nomination Committee’s amended proposal means that the Annual General Meeting agenda item 12, Election of Board members, is adjusted as follows:
Nomination Committee’s proposal:
a) Re-election of Peter Rothschild
b) No proposal
c) Re-election of Anders Ekblom
d) Re-election of Margareta Hagman
e) Re-election of Eva Idén
f) Re-election of Anthon Jahreskog
g) New election of Lilian Henningson Wikström
h) New election of Kristina Sjöblom Nygren
The Nomination Committee’s amended proposal does not entail any other consequences in the Nomination Committee’s already submitted proposals.
The Nomination Committee of Infant Bacterial Therapeutics AB (publ)
Infant Bacterial Therapeutics AB (publ) (“IBT”) is a clinical stage pharmaceutical company with a vision to develop drugs influencing the infant microbiome, and thereby prevent or treat rare diseases affecting infants.
IBT is currently developing its lead drug candidate IBP-9414 to prevent NEC in premature infants. IBP-9414 contains the active substance Lactobacillus reuteri, which is a human bacterial strain naturally present in breast milk. IBT is further pursuing a second rare disease program IBP-1016 for the treatment of an unmet medical need in gastroschisis, a severe congenital disorder in infants. By developing these drugs, IBT has the potential to fulfil unmet needs for diseases where there are currently no prevention or treatment therapies available.
IBT is listed on Nasdaq First North Premier with Erik Penser Bank as Certified Adviser.
Staffan Strömberg, CEO
Infant Bacterial Therapeutics AB
111 21 Stockholm
Phone: +46 8 410 145 55